

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION**

DISTRICT ADDRESS AND PHONE NUMBER 555 Winderly Place, Suite 200 Maitland, FL 32751 (407) 475-4700 Fax: (407) 475-4768.	DATE(S) OF INSPECTION 3/22/2016-3/25/2016
	FET NUMBER 3012161781

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED  
Jessica E. Dileo , Owner, Pharmacist

FIRM NAME Custom Meds, Inc.	STREET ADDRESS 102 E Highland Blvd
CITY, STATE, ZIP CODE, COUNTRY Inverness, FL 34452-4847	TYPE ESTABLISHMENT INSPECTED Non-sterile Compounding Pharmacy

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

**DURING AN INSPECTION OF YOUR FIRM I OBSERVED:**  
**OBSERVATION 1**  
 Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

Specifically, you stated your firm does not test finished drug products prior to distribution. For example, documentation states since 12/22/15 to the time of this inspection your firm prepared and distributed non-sterile drug products without testing to determine conformance with potency (topical and capsule products) and microbial limit specifications (topical products). Below are some examples:

- A. Creams and gels containing one or more active pharmaceutical ingredients such as testosterone, estradiol, lidocaine HCl, and pentoxifylline.
- B. Capsules containing ingredients such as progesterone and liothyronine sodium (T3).

**OBSERVATION 2**  
 Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, there are no established specifications for microbial limits for the non-sterile topical drug products made by your firm.

<b>SEE REVERSE OF THIS PAGE</b>	EMPLOYEE(S) SIGNATURE Jennifer Lalama, Investigator <i>Jennifer Lalama</i>	DATE ISSUED 3/25/2016
	<input checked="" type="checkbox"/> Jennifer Lalama Jennifer Lalama Investigator Signed by: Jennifer Lalama-2	

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION**

DISTRICT ADDRESS AND PHONE NUMBER

555 Winderly Place, Suite 200  
Maitland, FL 32751  
(407)475-4700 Fax: (407)475-4768

DATE(S) OF INSPECTION

3/22/2016-3/25/2016

FEI NUMBER

3012161781

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED

Jessica E. Dileo , Owner, Pharmacist

FIRM NAME

Custom Meds, Inc.

STREET ADDRESS

102 E Highland Blvd

CITY, STATE, ZIP CODE, COUNTRY

Inverness, FL 34452-4847

TYPE ESTABLISHMENT INSPECTED

Non-sterile Compounding Pharmacy

**OBSERVATION 3**


Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

Specifically, your firm does not test non-sterile topical preparations for presence of objectionable microorganisms prior to distribution.

**SEE REVERSE  
OF THIS PAGE**

EMPLOYEE(S) SIGNATURE

Jennifer Lalama, Investigator



3/25/2016

DATE ISSUED

3/25/2016

Jennifer Lalama  
Jennifer Lalama  
Investigator  
Signed by: Jennifer Lalama -S